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Aims Heart failure with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) individually
cause significant morbidity and mortality. Their coexistence is associated with even worse outcomes, partly due to
suboptimal heart failure therapy, especially underutilisation of beta-blockers. Our aim was to investigate outcomes
in HFrEF patients with and without COPD, and the effects of mineralocorticoid receptor antagonists (MRAs) on
outcomes.
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Methods
and results
We studied the effect of MRA therapy in a post-hoc pooled analysis of 4397 HFrEF patients in the RALES and
EMPHASIS-HF trials. The primary endpoint was the composite of heart failure hospitalisation or cardiovascular
death. A total of 625 (14.2%) of the 4397 patients had COPD. Patients with COPD were older, more often
male, and smokers, but less frequently treated with a beta-blocker. In patients with COPD, event rates (per 100
person-years) for the primary endpoint and for all-cause mortality were 25.2 (95% confidence interval 22.1–28.7)
and 17.2 (14.9–19.9), respectively, compared with 19.9 (18.8–21.1) and 12.8 (12.0–13.7) in participants without
COPD. The risks of all-cause hospitalisation and sudden death were also higher in patients with COPD. The benefit
of MRA, compared with placebo, was consistent in patients with or without COPD for all outcomes, e.g. hazard ratio
for the primary outcome 0.66 (0.50–0.85) for COPD and 0.65 (0.58–0.73) for no COPD (interaction p = 0.93).
MRA-induced hyperkalaemia was less frequent in patients with COPD.
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Conclusions In RALES and EMPHASIS-HF, one-in-seven patients with HFrEF had coexisting COPD. HFrEF patients with COPD
had worse outcomes than those without. The benefits of MRAs were consistent, regardless of COPD status.
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Introduction
Chronic obstructive pulmonary disease (COPD) is more common
in patients with heart failure and reduced ejection fraction (HFrEF)
than in the general population because each condition can arise
as a complication of smoking.1–5 Concomitant COPD is associ-
ated with even worse symptoms, functional limitation and clinical
outcomes than in HFrEF alone.6–8 Coexisting COPD also creates
therapeutic difficulties. Beta-blockers are a key, life-saving treat-
ment for HFrEF, but may not be tolerated in people with COPD,
antagonise the effects of beta-2 adrenoceptor agonists, a core
therapy for COPD, and can cause exacerbations of COPD.9 How-
ever, many if not most patients with COPD can tolerate a beta-1
selective blocker and this treatment should not be withheld in
patients with COPD. Conversely, beta-2 adrenoceptor agonists can
cause tachycardia and hypokalaemia, neither of which is desirable
in HFrEF. Both hypokalaemia and methylxanthines, another therapy
for COPD, can predispose to arrhythmias. Corticosteroids, espe-
cially if given orally, cause fluid retention which is undesirable in
HFrEF and in COPD, which is itself a sodium- and water-retaining
state (although both methylxanthines and systemic corticosteroids
are used in a small minority of patients in most countries).
Clearly, it would be ideal to be able to use all other effec-
tive therapies for HFrEF in patients with concomitant COPD in
view of their heightened risk of adverse outcomes and poten-
tial intolerance of beta-blockers. In many ways mineralocorticoid
receptor antagonists (MRAs) seem an ideal treatment for patients
with both HFrEF and COPD. Each condition is associated with an
increase in plasma aldosterone concentration and MRAs should
help counter fluid retention, block any adverse effects of exoge-
nous corticosteroids at the mineralocorticoid receptor and miti-
gate the risk of hypokalaemia with beta-2 agonists.4,10–12 In addi-
tion, MRAs seem to attenuate pathogenic vascular remodelling in
the lungs, and right ventricular failure, in experimental models of
pulmonary hypertension.13–17 These problems also occur as sec-
ondary complications in some patients with COPD. Surprisingly,
however, in a large Danish nationwide cohort, use of spironolac-
tone in such patients was associated with a higher mortality than
no use of spironolactone, the opposite of what was found for
beta-blockers and renin–angiotensin system antagonists.18 While
this unexpected finding may reflect the specific characteristics of
the Danish patients (all of whom had right heart failure) or unmea-
sured or uncorrected confounding in an observational cohort, it
does suggest the subject merits further investigation. MRAs can
cause worsening of kidney function and renal dysfunction is com-
mon in both HFrEF and COPD. MRAs can also lead to hyper-
kalaemia which may lead to ventricular arrhythmias and patients
with the combination of HFrEF and COPD may be particularly vul-
nerable to these.19–21 Despite the Danish observational data and
potential for hyperkalaemia to increase the risk of arrhythmias, our
hypothesis was that MRAs would be as beneficial in HFrEF patients
with COPD, as in those without. Fortunately, there are prospective
randomised controlled trial data which allow us to examine both
the efficacy and safety of MRAs in HFrEF patients with concomi-
tant COPD. Therefore, in a post hoc analysis, we examined the



















































































.. enrolled in the RALES (Randomized Aldactone Evaluation Study)
and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure) trials.22,23
Methods
RALES and EMPHASIS-HF were each prospective, double-blind,
placebo-controlled, event-driven mortality/morbidity trials. Each trial
received ethics committee approval and all participants provided
written informed consent. Their design, baseline findings, and primary
results are published in full.22–25 The mean follow-up in RALES was
24 months and median follow-up in EMPHASIS-HF was 21 months.
Trial patients
In RALES, patients with New York Heart Association (NYHA)
functional class III or IV heart failure, a left ventricular ejection
fraction (LVEF) of ≤35% and receiving current treatment with an
angiotensin-converting enzyme (ACE) inhibitor (if tolerated) and a
loop diuretic, were randomly assigned to receive either spironolactone
or placebo. In EMPHASIS-HF, patients with NYHA functional class II
heart failure, LVEF of ≤30% (or ≤35% if QRS duration >130 ms) and
receiving optimal ACE inhibitor/angiotensin receptor blocker (ARB)
and beta-blocker therapy (unless contraindicated), were randomly
assigned to either eplerenone or placebo. Exclusion criteria are
detailed in the design and results papers.22,25
There was no exclusion related to COPD in either trial, although
investigators were asked to exclude patients with another clini-
cally important condition (e.g. cancer) likely to greatly shorten life
expectancy.
Trial treatments
In RALES, patients were assigned to a starting dosage of 25 mg of
spironolactone once daily or a matching placebo. After 8 weeks, the
dose could be increased to 50 mg once daily ‘if the patient showed
signs or symptoms of progression of heart failure without evidence of
hyperkalaemia’. In EMPHASIS-HF, eplerenone was started at a dose of
25 mg once daily and was increased after 4 weeks to 50 mg once daily
(or started at 25 mg on alternate days, and increased to 25 mg daily, if
the estimated glomerular filtration rate was 30 to 49 mL/min/1.73 m2),
provided the serum potassium level was no more than 5.0 mmol/L.
Identification of chronic obstructive
pulmonary disease
Diagnosis of COPD was reported by investigators in the medical
history section of the case report forms in each of RALES and
EMPHASIS-HF. There was a specific ‘yes or no’ question about COPD,
but no specific criteria were provided for a diagnosis of COPD.
Study outcomes
The primary outcome in RALES was death from any cause and
in EMPHASIS-HF it was time to first occurrence of heart failure
hospitalisation or death from a cardiovascular cause. The latter was
used as the primary endpoint in the present analysis. We also examined
the components of this composite, non-cardiovascular and all-cause
death, as well as pump failure and sudden cardiac death.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics according to chronic obstructive pulmonary disease status
All patients (n = 4397)a Without COPD (n = 3772) With COPD (n = 625) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 67.4 ± 9.6 67.1 ± 9.8 69.1 ± 7.9 <0.001
Women 1056 (24.0) 946 (25.1) 110 (17.6) <0.001
Race <0.001
White 3706 (84.3) 3140 (83.2) 566 (90.6)
Black 187 (4.3) 178 (4.7) 9 (1.4)
Asian 347 (7.9) 308 (8.2) 39 (6.2)
Other 157 (3.6) 146 (3.9) 11 (1.8)
Heart rate (bpm) 75.2 ± 13.9 74.9 ±13.8 76.8 ±13.9 0.001
SBP (mmHg) 123.4 ±18.2 123.4 ± 18.3 123.2 ±17.4 0.80
DBP (mmHg) 74.6 ± 10.8 74.7 ±10.7 74.1 ± 11.0 0.16
Hypertension 2208 (50.2) 1857 (49.2) 351 (56.2) 0.001
Diabetes 1228 (27.9) 1054 (27.9) 174 (27.8) 0.96
Myocardial infarction 1852 (42.1) 1571 (41.6) 281 (45.0) 0.12
Atrial fibrillation/flutter 1026 (23.3) 861 (22.8) 165 (26.4) 0.051
Ischaemic CVA 248 (5.7) 199 (5.3) 49 (7.9) 0.010
HF aetiology 0.22
Ischaemic 2792 (63.6) 2383 (63.2) 409 (65.8)
Non-ischaemic 1600 (36.4) 1387 (36.8) 213 (34.2)
NYHA class 0.19
II 2740 (62.3) 2349 (62.3) 391 (62.6)
III 1173 (26.7) 1021 (27.1) 152 (24.3)
IV 483 (11.0) 401 (10.6) 82 (13.1)
LVEF (%) 25.8 ± 5.6 25.9 ± 5.5 25.6 ± 5.8 0.30
eGFR (mL/min/1.73 m2) 68.6 ± 22.4 68.6 ± 22.4 68.3 ± 22.4 0.74
eGFR<60 mL/min/1.73 m2 1702 (38.8) 1460 (38.8) 242 (38.8) 0.97
Creatinine (mg/dL) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 0.24
Potassium (mmol/L) 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 0.054
Diuretic 3826 (87.3) 3283 (87.3) 543 (87.6) 0.83
ACEi/ARB 4145 (94.6) 3552 (94.4) 593 (95.6) 0.21
Beta-blocker 2543 (58.0) 2234 (59.4) 309 (49.8) <0.001
Digoxin 1955 (44.6) 1680 (44.7) 275 (44.4) 0.89
Data are presented as mean ± standard deviation for continuous measures, and n (%) for categorical measures.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DBP,
diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic
blood pressure.
aFor 4397 patients of the 4400 randomised because COPD status was not recorded in 3 patients.
Statistical analysis
In order to maximise the number of COPD patients and events, as
well as cover the full spectrum of heart failure symptom severity
(NYHA class II to IV), we merged the RALES and EMPHASIS-HF
databases. Certain baseline data were collected in EMPHASIS-HF,
but not RALES. Hence, the baseline analysis is presented in two
tables: Table 1 (baseline characteristics collected in both RALES and
EMPHASIS-HF) and online supplementary Table S1 (additional baseline
data collected in EMPHASIS-HF only).
Baseline characteristics are reported as means and standard devi-
ations for continuous variables and frequencies with percentages for
categorical variables. Time-to-event endpoints were evaluated using
Kaplan–Meier estimates and Cox proportional hazard models, strat-
ified according to trial and adjusted for randomised treatment group
to estimate hazard ratios (HRs) with 95% confidence intervals (CIs).
Along with crude HRs, we also report HRs adjusted for age, sex,
race, heart rate, systolic blood pressure, NYHA classification, LVEF,

























. diabetes and atrial fibrillation. In a sensitivity analysis, we also adjusted
for beta-blocker use at baseline, given the anticipated imbalance in the
use of these drugs between patients with and without COPD and their
powerful effect of clinical outcomes in HFrEF.
The treatment effect for each time-to-event endpoint was estimated
using Cox models with an interaction term between baseline COPD
status and treatment group. The interaction between COPD status
and effect of randomised treatment on adverse events and study drug
discontinuation was analysed using a logistic regression model with an
interaction term between baseline COPD status and treatment.
A P-value of < 0.05 was considered significant. Statistical analyses
were conducted using STATA version 16.0 (Stata Corp., College
Station, TX, USA).
Results
Overall, 4397 patients were included in the analysis, of whom 2212
were randomised to placebo and 2185 to an MRA. Of the included
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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patients, 625 (14.2%) had COPD: 321 (14.7%) in the MRA group
and 304 (13.7%) in the placebo group.
Baseline characteristics according
to chronic obstructive pulmonary
disease status
The baseline characteristics of patients in the combined RALES and
EMPHASIS-HF dataset are shown in Table 1 according to COPD
status. Patients with COPD were older and more often men.
They were also more likely than patients without COPD to have
a history of hypertension, atrial fibrillation and stroke but not of
coronary heart disease. NYHA functional class distribution, LVEF
and kidney function were similar in each COPD subgroup.
Patients with COPD were significantly less likely to be treated
with a beta-blocker. Data on beta-blocker selectivity were not
available.
Online supplementary Table S1 contains additional data collected
in EMPHASIS-HF only. In EMPHASIS-HF, patients with COPD were
more often current smokers (21.7%) than those without COPD
(8.9%).
Clinical outcomes according to chronic
obstructive pulmonary disease status
The incidence rate (per 100 person-years) and unadjusted risk
of most outcomes examined were higher in patients with COPD
compared to those without (the exception was pump failure death,
although numbers of this event in the COPD groups were small).
The elevated risks were attenuated by multivariable adjustment
(Table 2).
Primary outcome (composite of heart failure
hospitalisation or cardiovascular death)
The event rates were 25.2 (95% CI 22.1–28.7) in patients with
COPD, vs. 19.9 (95% CI 18.8–21.1) in those without COPD with
unadjusted HR 1.25 (95% CI 1.08–1.44), using patients without
COPD as the reference group (Figure 1). The elevated risk was
attenuated to HR 1.16 (95% CI 1.00–1.35) after adjustment for
standard prognostic variables. A similar picture was seen for the
components of the composite outcome.
Mortality
The higher rate of cardiovascular mortality in patients with COPD
was driven by an elevated risk of sudden death compared with
pump failure death, compared to patients without COPD: unad-
justed HR 1.44 (95% CI 1.09–1.91) for sudden death vs. 1.14 (95%
CI 0.88–1.49) for pump failure death.
The rate of non-cardiovascular mortality, and therefore all-cause
mortality, was also higher in patients with COPD, with a greater
elevation in risk of non-cardiovascular death vs. cardiovascular
death, compared to participants without COPD [unadjusted
HR 1.82 (95% CI 1.28–2.58) for non-cardiovascular death vs.



















































































.. Examination of causes of non-cardiovascular deaths showed
an excess of deaths due to infection/sepsis in patients with
COPD compared to those without COPD (online supplementary
Figure S1).
Hospitalisations
Patients with COPD had higher all-cause, heart failure and
non-cardiovascular hospitalisations [unadjusted HR 1.33 (95%
CI 1.17–1.51), 1.25 (95% CI 1.05–1.49) and 1.79 (95% CI
1.44–2.22), respectively]. In contrast to heart failure hospitalisa-
tions, the elevated risk of all-cause and non-cardiovascular hospi-
talisations persisted with multivariable adjustment.
In the sensitivity analyses, further adjusting for beta-blocker
slightly attenuated the excess risk related to COPD, more so for
heart failure hospitalisation than the other outcomes.
These findings were consistent when RALES and EMPHASIS-HF
were analysed separately (online supplementary Tables S2 and S3).
Efficacy of mineralocorticoid receptor
antagonists according to chronic
obstructive pulmonary disease status
The benefits of MRAs, compared with placebo, were consistent in
patients with and without COPD for all mortality and hospitali-
sation outcomes (Table 3 and Figure 1). The HR for the primary
outcome was 0.66 (95% CI 0.50–0.85) in patients with COPD and
0.65 (95% CI 0.58–0.73) in patients without COPD (P-value for
interaction =0.93). The HR for all-cause mortality was 0.77 (95%
CI 0.58–1.03) in patients with COPD and 0.72 (95% CI 0.63–0.82)
in patients without COPD (P-value for interaction=0.65) (Figure 1).
These findings were consistent when RALES and EMPHASIS-HF
were analysed separately (online supplementary Tables S4 and S5).
Safety of mineralocorticoid receptor
antagonists according to chronic
obstructive pulmonary disease status
Mild hyperkalaemia (potassium >5.5 mmol/L) was more com-
mon on an MRA than on placebo in patients with or without
COPD although moderate-to-severe hyperkalaemia (potassium
>6.0 mmol/L) appeared to be increased by MRA therapy only in
patients without COPD (Table 4).
Discussion
The prevalence of COPD in this combined RALES and
EMPHASIS-HF cohort (14.2%) was similar to that reported
in other large-scale HFrEF trials including the Prospective
Comparison of ARNI with an ACE-Inhibitor to Determine
Impact on Global Mortality and morbidity in Heart Failure trial
(PARADIGM-HF; prevalence 12.9%), the Dapagliflozin And Pre-
vention of Adverse-outcomes in Heart Failure trial (DAPA-HF;
prevalence 12.3%) and in a ‘real-world’ study (the European
Society of Cardiology long-term registry; prevalence 14.1%).26–28
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Event rate (per 100 patient-years) and risk of study endpoints according to chronic obstructive pulmonary
disease status
Without COPD (n = 3772) With COPD (n = 625) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HF hospitalisation or cardiovascular death
Events, n (%) 1195 (31.7) 227 (36.3)
Event rate per 100 patient-years 19.9 (18.8–21.1) 25.2 (22.1–28.7)
Unadjusted HR 1.00 (ref.) 1.25 (1.08–1.44) 0.002
Adjusted HRa 1.00 (ref.) 1.16 (1.00–1.35) 0.045
Adjusted HRb 1.00 (ref.) 1.12 (0.96–1.30) 0.139
HF hospitalisation
Events, n (%) 783 (20.8) 150 (24.0)
Event rate per 100 patient-years 13.1 (12.2–14.0) 16.6 (14.2–19.5)
Unadjusted HR 1.00 (ref.) 1.25 (1.05–1.49) 0.011
Adjusted HRa 1.00 (ref.) 1.17 (0.98–1.40) 0.091
Adjusted HRb 1.00 (ref.) 1.12 (0.93–1.34) 0.225
All-cause hospitalisation
Events, n (%) 1510 (40.0) 294 (47.0)
Event rate per 100 patient-years 29.2 (27.8–30.7) 39.9 (35.6–44.7)
Unadjusted HR 1.00 (ref.) 1.33 (1.17–1.51) <0.001
Adjusted HRa 1.00 (ref.) 1.25 (1.10–1.42) 0.001
Adjusted HRb 1.00 (ref.) 1.23 (1.08–1.40) 0.002
Non-cardiovascular hospitalisation
Events, n (%) 394 (10.4) 105 (16.8)
Event rate per 100 patient-years 6.8 (6.1–7.5) 12.2 (10.0–14.8)
Unadjusted HR 1.00 (ref.) 1.79 (1.44–2.22) <0.001
Adjusted HRa 1.00 (ref.) 1.68 (1.34–2.10) <0.001
Adjusted HRb 1.00 (ref.) 1.69 (1.35–2.12) <0.001
Cardiovascular death
Events, n (%) 729 (19.3) 142 (22.7)
Event rate per 100 patient-years 10.8 (10.0–11.6) 13.4 (11.4–15.8)
Unadjusted HR 1.00 (ref.) 1.25 (1.04–1.49) 0.016
Adjusted HRa 1.00 (ref.) 1.13 (0.93–1.36) 0.211
Adjusted HRb 1.00 (ref.) 1.10 (0.91–1.32) 0.329
Non-cardiovascular death
Events, n (%) 142 (3.8) 40 (6.4)
Event rate per 100 patient-years 2.1 (1.8–2.5) 3.8 (2.8–5.2)
Unadjusted HR 1.00 (ref.) 1.82 (1.28–2.58) 0.001
Adjusted HRa 1.00 (ref.) 1.85 (1.29–2.65) 0.001
Adjusted HRb 1.00 (ref.) 1.81 (1.26–2.60) 0.001
All-cause death
Events, n (%) 871 (23.1) 182 (29.1)
Event rate per 100 patient-years 12.8 (12.0–13.7) 17.2 (14.9–19.9)
Unadjusted HR 1.00 (ref.) 1.34 (1.14–1.57) <0.001
Adjusted HRa 1.00 (ref.) 1.24 (1.05–1.46) 0.010
Adjusted HRb 1.00 (ref.) 1.21 (1.03–1.43) 0.024
Pump failure death
Events, n (%) 358 (9.5) 64 (10.2)
Event rate per 100 patient-years 5.3 (4.7–5.8) 6.1 (4.7–7.7)
Unadjusted HR 1.00 (ref.) 1.14 (0.88–1.49) 0.327
Adjusted HRa 1.00 (ref.) 0.96 (0.73–1.27) 0.778
Adjusted HRb 1.00 (ref.) 0.94 (0.71–1.24) 0.656
Sudden cardiac death
Events, n (%) 267 (7.1) 60 (9.6)
Event rate per 100 patient-years 3.9 (3.5–4.4) 5.7 (4.4–7.3)
Unadjusted HR 1.00 (ref.) 1.44 (1.09–1.91) 0.011
Adjusted HRa 1.00 (ref.) 1.35 (1.01–1.80) 0.042
Adjusted HRb 1.00 (ref.) 1.31 (0.98–1.76) 0.064
COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio.
aModel adjusted for age, sex, race, heart rate, systolic blood pressure, New York Heart Association classification, left ventricular ejection fraction, estimated glomerular
filtration rate, history of myocardial infarction, diabetes and atrial fibrillation.
bAdjusted as for ‘a’ with additional adjustment for beta-blocker prescription at baseline.
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Figure 1 Kaplan–Meier curves for key outcomes, according to baseline chronic obstructive pulmonary disease (COPD) status and
randomised treatment. The primary outcome was the composite of heart failure hospitalisation and death from cardiovascular causes. MRA,
mineralocorticoid receptor antagonist.
As expected, patients with COPD in RALES and EMPHASIS-HF
were older and more often male than those without COPD,
smoked more (in EMPHASIS-HF) and had more hypertension and
atrial fibrillation, although not diabetes, coronary artery disease,
or chronic kidney disease.7,8,29,30 There was also no difference
in LVEF or NYHA class between the two groups. Therefore,










. recognised prognostic factors, participants with COPD were at
considerably higher risk of hospitalisation and death, as has been
documented in other studies. As anticipated, some of the excess
mortality in patients with COPD was due to non-cardiovascular
causes, primarily due to infection/sepsis. Interestingly, however,
we found a higher risk of sudden death in patients with COPD,
compared with those without. We are not aware of a prior
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Clinical outcomes and treatment effect according to chronic obstructive pulmonary disease status
(mineralocorticoid receptor antagonist vs. placebo event rates and hazard ratios with 95% confidence interval)
Without COPD With COPD P-value for
interaction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo (n = 1908) MRA (n = 1864) Placebo (n = 304) MRA (n = 321)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HF hospitalisation or cardiovascular death
Events, n (%) 700 (36.7) 495 (26.6) 128 (42.1) 99 (30.8)
Event rate per 100 patient-years 24.4 (22.6–26.2) 15.8 (14.5–17.3) 31.5 (26.5–37.5) 20.0 (16.4–24.3)
Unadjusted HR 0.65 (0.58–0.73) 0.66 (0.50–0.85) 0.93
HF hospitalisation
Events, n (%) 465 (24.4) 318 (17.1) 88 (28.9) 62 (19.3)
Event rate per 100 patient-years 16.2 (14.8–17.7) 10.2 (9.1–11.4) 21.7 (17.6–26.7) 12.5 (9.8–16.1)
Unadjusted HR 0.64 (0.55–0.73) 0.59 (0.43–0.82) 0.79
All-cause hospitalisation
Events, n (%) 814 (42.7) 696 (37.3) 158 (52.0) 136 (42.4)
Event rate per 100 patient-years 32.8 (30.6–35.1) 25.9 (24.1–27.9) 48.6 (41.6–56.8) 33.0 (27.9–39.1)
Unadjusted HR 0.80 (0.72–0.89) 0.71 (0.57–0.90) 0.28
Non-cardiovascular hospitalisation
Events, n (%) 185 (9.7) 209 (11.2) 53 (17.4) 52 (16.2)
Event rate per 100 patient-years 6.5 (5.6–7.5) 7.0 (6.1–8.1) 13.9 (10.6–18.2) 10.8 (8.2–14.2)
Unadjusted HR 1.06 (0.87–1.30) 0.78 (0.53–1.14) 0.16
Cardiovascular death
Events, n (%) 420 (22.0) 309 (16.6) 79 (26.0) 63 (19.6)
Event rate per 100 patient-years 12.5 (11.4–13.8) 9.0 (8.1–10.1) 16.1 (12.9–20.1) 11.1 (8.7–14.3)
Unadjusted HR 0.72 (0.62–0.83) 0.72 (0.52–1.00) 1.00
All-cause death
Events, n (%) 501 (26.3) 370 (19.8) 98 (32.2) 84 (26.2)
Event rate per 100 patient-years 15.0 (13.7–16.3) 10.8 (9.7–11.9) 20.0 (16.4–24.3) 14.8 (12.0–18.4)
Unadjusted HR 0.72 (0.63–0.82) 0.77 (0.58–1.03) 0.65
Pump failure death
Events, n (%) 212 (11.1) 146 (7.8) 38 (12.5) 26 (8.1)
Event rate per 100 patient-years 6.3 (5.5–7.2) 4.3 (3.6–5.0) 7.7 (5.6–10.6) 4.6 (3.1–6.7)
Unadjusted HR 0.67 (0.54–0.83) 0.61 (0.37–1.01) 0.80
Sudden cardiac death
Events, n (%) 154 (8.1) 113 (6.1) 32 (10.5) 28 (8.7)
Event rate per 100 patient-years 4.6 (3.9–5.4) 3.3 (2.7–4.0) 6.5 (4.6–9.2) 4.9 (3.4–7.2)
Unadjusted HR 0.71 (0.56–0.91) 0.80 (0.48–1.33) 0.73
COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist.
report of this finding. It suggests the possibility of a proarrhyth-
mic milieu in patients with COPD related, for example, to beta-2
agonist induced hypokalaemia, methylxanthine and digoxin use, and
hypoxaemia, as well as loss of the antiarrhythmic protection of
beta-blockers. Interestingly, the excess risk of sudden death (and
heart failure hospitalisation) was slightly attenuated by adjustment
for baseline beta-blocker use. Concomitant right ventricular dys-
function, which is common in patients with COPD, may further
elevate the risk of arrhythmias and sudden death.3,4,19–21
Indeed, because some patients with COPD cannot tolerate
beta-blockers, it is even more important that other treatments are
available and shown to be effective in HFrEF patients with con-
comitant COPD. In fact, MRAs may be particularly suited to HFrEF
patients with COPD. The importance in avoiding hyperkalaemia
has already been highlighted. COPD is itself a fluid-retaining state
associated with hyperaldosteronism.4,10–12 The harmful effects of
























.. may also have detrimental effects in the pulmonary vasculature,
which is especially relevant given the propensity of patients with
COPD to develop pulmonary hypertension.13–17
We showed that MRAs have substantial benefits in HFrEF
patients with COPD. The proportional risk reductions in all
key outcomes were similar to those obtained in HFrEF patients
without COPD, with around a 35% relative risk reduction in
the primary composite endpoint and a 30% reduction in cardio-
vascular death. The absolute risk reductions were also large. In
both patient subgroups, the number needed to treat to prevent
one patient experiencing the primary endpoint was only 10–12
over a median follow-up of approximately 2 years. Our findings
appear to refute those of the Danish observational study which
reported higher mortality in patients with COPD and right heart
failure using spironolactone. While this is likely due to unmeasured
or uncorrected confounding in the Danish cohort, the patients
in the two studies were different. All patients in RALES and
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Adverse effects of interest and permanent study drug discontinuation according to randomised treatment
and chronic obstructive pulmonary disease status at baseline
Event Without COPD With COPD P-value for
interaction









. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hypotension
Events, n (%) 76 (4.0) 86 (4.6) 10 (3.3) 14 (4.4)
Unadjusted OR 1.17 (0.85–1.60) 1.36 (0.59–3.12) 0.76
Creatinine≥2.5 mg/dL
Events, n (%) 59 (3.1) 83 (4.5) 6 (2.0) 14 (4.4)
Unadjusted OR 1.47 (1.05–2.08) 2.38 (0.89–6.33) 0.39
Creatinine≥3.0 mg/dL
Events, n (%) 25 (1.3) 32 (1.7) 3 (1.0) 7 (2.2)
Unadjusted OR 1.32 (0.78–2.24) 2.32 (0.59–9.12) 0.47
Potassium>5.5 mmol/L
Events, n (%) 111 (5.8) 244 (13.1) 22 (7.2) 42 (13.1)
Unadjusted OR 2.44 (1.93–3.08) 1.95 (1.13–3.36) 0.44
Potassium>6.0 mmol/L
Events, n (%) 23 (1.2) 60 (3.2) 9 (3.0) 6 (1.9)
Unadjusted OR 2.73 (1.68–4.43) 0.63 (0.22–1.79) 0.01
Potassium<3.5 mmol/L
Events, n (%) 263 (13.8) 130 (7.0) 36 (11.8) 24 (7.5)
Unadjusted OR 0.47 (0.38–0.58) 0.60 (0.35–1.04) 0.41
Study drug discontinuation (all-cause)
Events, n (%) 377 (19.8) 365 (19.6) 64 (21.1) 71 (22.1)
Unadjusted OR 0.99 (0.84–1.16) 1.08 (0.73–1.58) 0.73
COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid receptor antagonist; OR, odds ratio with 95% confidence interval.
EMPHASIS-HF had HFrEF whereas the patients in the Danish
observational study were selected because of a diagnosis of
COPD and pulmonary hypertension and treatment with diuretics;
approximately 60% had a concomitant diagnosis of heart failure
(ejection phenotype not defined).18
Finally, MRA therapy was as well tolerated in patients with
COPD, as in those without. While severe hyperkalaemia was more
common in placebo-treated patients with COPD, compared to
those without COPD, severe hyperkalaemia was significantly less
common in MRA-treated patients with COPD, compared to those
without COPD, potentially due to the ‘protective’ effect of chronic
respiratory acidosis, metabolic alkalosis, and corticosteroid ther-
apy or beta-agonist treatment, or both.
Use of MRA in patients with HFrEF has been increasing with
rates in patients with COPD, compared with no COPD, of 65.6%
vs. 71.8% in DAPA-HF (2019), 54.2% vs. 55.8% in PARADIGM-HF
(2014) and 57.0% vs. 52.3% in the ESC Long-Term Registry (data
collected 2011–13).
Translational outlook
Although the exact reasons why patients with HFrEF and concomi-
tant COPD are at such high risk are unknown, these data show the
risk of sudden death is particularly elevated, compared to patients
without COPD. This may be an area of additional research into







































This study has several limitations. The analyses conducted were not
pre-specified. COPD was investigator-reported, COPD severity
was not recorded, and we did not know in whom spirometry
had been performed. The patients studied were selected for
a clinical trial and will differ from those in ordinary every-day
practice. Biomarkers and quality of life data were not collected, and
smoking status was only documented in EMPHASIS-HF (and not
in RALES).
Conclusion
This analysis highlights the importance of MRA therapy in HFrEF
patients with COPD. In the RALES and EMPHASIS-HF trials,
one-in-seven patients with HFrEF had coexisting COPD. Patients
with HFrEF and concomitant COPD had much worse outcomes
but the benefit of MRA therapy was consistent across all mor-
bidity and mortality outcomes examined, regardless of COPD
status.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Effects of MRAs in HFrEF patients with COPD 9
Funding
This work was supported by the British Heart Foundation Centre
of Research Excellence Grant RE/18/6/34217.
Conflict of interest: J.J.V.M. employer has been paid
by Cardiorentis, Amgen, Oxford University/Bayer, Abbvie,
Bristol-Myers Squibb, Kings College Hospital/Kidney Research
UK/Vifor-Fresenius, Theracos, Pfizer, Merck, Novartis, Bayer,
DalCor Pharmaceuticals, GlaxoSmithKline. All payments for
meetings-related travel and accommodation were made through a
Consultancy with the University of Glasgow, and J.J.V.M. has not
received personal payments in relation to any trials or drugs. B.P.
reports personal fees (consulting) from Bayer, KBP Pharmaceuti-
cals, AstraZeneca, Relypsa/Vifor, Sanofi, sc Pharmaceuticals, Sarfez
pharmaceuticals, Stealth Peptides, Cereno Scientific, SQinnova-
tions, G3 pharmaceuticals, Ardelyx and Tricida; stock options from
KBP Pharmaceuticals, sc Pharmaceuticals, Sarfez pharmaceuticals,
Relypsa, Cereno scientific, SQinnovations, G3 pharmaceuticals,
Ardelyx and Tricida; patent for site specific delivery of eplerenone
to the myocardium US patent Number 9931412. F.Z. reports
personal fees for Steering Committee membership from Janssen,
Bayer, Pfizer, Novartis, Boston Scientific, Resmed, Takeda, Gen-
eral Electric, and Boehringer Ingelheim; consultancy for Amgen,
CVRx, Quantum Genomics, Relypsa, ZS Pharma, AstraZeneca,
GSK; founder of Cardiovascular Clinical Trialists (CVCT) and of
CardioRenal. Profs McMurray, Pitt, Swedberg, van Veldhuisen, and
Zannad received remuneration from Pfizer as members of the
EMPHASIS-HF Executive Steering Committee. P.S.J. has received
consulting, advisory board, and speaker’s fees from Novartis, advi-
sory board fees from Cytokinetics, and a grant from Boehringer
Ingelheim. J.P.F. has received consulting fees from Boehringer
Ingelheim. All other authors have nothing to disclose.
References
1. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ.
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and
epidemiology. Eur J Heart Fail 2009;11:130–139.
2. Güder G, Rutten FH. Comorbidity of heart failure and chronic obstruc-
tive pulmonary disease: more than coincidence. Curr Heart Fail Rep 2014;11:
337–346.
3. Jaiswal A, Chichra A, Nguyen VQ, Gadiraju TV, Le Jemtel TH. Challenges
in the management of patients with chronic obstructive pulmonary disease
and heart failure with reduced ejection fraction. Curr Heart Fail Rep 2016;13:
30–36.
4. Horodinschi RN, Bratu OG, Dediu GN, Pantea Stoian A, Motofei I, Diaconu CC.
Heart failure and chronic obstructive pulmonary disease: a review. Acta Cardiol
2020;75:97–104.
5. Pellicori P, Cleland JGF, Clark AL. Chronic obstructive pulmonary disease and
heart failure: a breathless conspiracy. Heart Fail Clin 2020;16:33–44.
6. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pul-
monary disease: the challenges facing physicians and health services. Eur Heart J
2013;34:2795–2803.
7. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL, Keteyian SJ, Kitzman
DW, Whellan DJ, Ellis SJ, O’Connor CM. Clinical characteristics, response
to exercise training, and outcomes in patients with heart failure and chronic
obstructive pulmonary disease: findings from Heart Failure and A Controlled
Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). Am Heart J
2013;165:193–199.
8. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Robertson M,
Ford I; SHIFT Investigators. Clinical profiles and outcomes in patients with chronic
heart failure and chronic obstructive pulmonary disease: an efficacy and safety



















































































.. 9. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wik-
strand J, McMurray JJ. Heart failure and chronic obstructive pulmonary
disease: the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol
2011;57:2127–2138.
10. Anand IS, Chandrashekhar Y, Ferrari R, Sarma R, Guleria R, Jindal SK, Wahi PL,
Poole-Wilson PA, Harris P. Pathogenesis of congestive state in chronic obstruc-
tive pulmonary disease. Studies of body water and sodium, renal function, hemo-
dynamics, and plasma hormones during edema and after recovery. Circulation
1992;86:12–21.
11. Stewart AG, Waterhouse JC, Billings CG, Baylis PH, Howard P. Hormonal, renal,
and autonomic nerve factors involved in the excretion of sodium and water during
dynamic salt and water loading in hypoxaemic chronic obstructive pulmonary
disease. Thorax 1995;50:838–845.
12. de Leeuw PW, Dees A. Fluid homeostasis in chronic obstructive lung disease.
Eur Respir J Suppl 2003;46:33s–40s.
13. Omidkhoda N, Vakilian F, Mohammadpour AH, Sathyapalan T, Sahebkar A.
Aldosterone and mineralocorticoid receptor antagonists on pulmonary
hypertension and right ventricular failure: a review. Curr Pharm Des
2020;26:3862–3870.
14. Safdar Z, Frost A, Basant A, Deswal A, O’Brian Smith E, Entman M. Spironolac-
tone in pulmonary arterial hypertension: results of a cross-over study. Pulm Circ
2020;10:2045894019898030.
15. Wang Y, Zhong B, Wu Q, Zhu T, Wang Y, Zhang M. Aldosterone contributed to
pulmonary arterial hypertension development via stimulating aquaporin expres-
sion and pulmonary arterial smooth muscle cells proliferation. Pharmacology
2020;105:405–415.
16. Zelt JGE, Chaudhary KR, Cadete VJ, Mielniczuk LM, Stewart DJ. Medical
therapy for heart failure associated with pulmonary hypertension. Circ Res
2019;124:1551–1567.
17. Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, Kiely DG,
Grimminger F, Ghofrani HA, Weissmann N, Seeger W, Lawrie A, Schermuly RT,
Kojonazarov B. Eplerenone attenuates pathological pulmonary vascular rather
than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulm
Med 2018;18:41.
18. Andersson C, Hansen PW, Steffensen IE, Andreasen C, Weeke PE, Køber L,
Gislason GH, Torp-Pedersen C. Mortality associated with cardiovascular drugs
in patients with chronic obstructive pulmonary disease and right-sided heart
failure – A Danish nationwide registry-based study. Eur J Intern Med 2019;63:
56–61.
19. Leong P, Macdonald MI, Ko BS, Bardin PG. Coexisting chronic obstructive
pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and
therapeutic challenge. Med J Aust 2019;210:417–423.
20. van den Berg ME, Stricker BH, Brusselle GG, Lahousse L. Chronic obstructive pul-
monary disease and sudden cardiac death: a systematic review. Trends Cardiovasc
Med 2016;26:606–613.
21. Goudis CA, Konstantinidis AK, Ntalas IV, Korantzopoulos P. Electrocardio-
graphic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary
disease. Int J Cardiol 2015;199:264–273.
22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
The effect of spironolactone on morbidity and mortality in patients with severe
heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med
1999;341:709–717.
23. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J,
Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic
heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
24. Pitt D. ACE inhibitor co-therapy in patients with heart failure: rationale for
the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 1995;16:
107–110.
25. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K,
Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients
Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart
Fail 2010;12:617–622.
26. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL,
Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and
Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med 2014;371:993–1004.
27. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA,
Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra
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